Company Directory - Vaxcyte, Inc.
Company Details - Vaxcyte, Inc.
Vaxcyte, Inc.
WebsiteISIN: US92261D1054
A biotechnology company that focuses on developing transformative vaccines to protect against infectious diseases, particularly for serious pathogens.
CCI Score
CCI Score: Vaxcyte, Inc.
-29.12
0.02%
Latest Event
Vaxcyte Lobbying Spending in 2024
According to OpenSecrets data, Vaxcyte Inc spent $30,000 on federal lobbying activities during 2024. The expenditure reflects the company's engagement in political advocacy, which raises concerns about corporate influence on public policy.
Take Action
So what can you do? It's time to make tough choices. Where will you cast your vote?
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
ACCOMPLICE
Vaxcyte, Inc. is currently rated as an Accomplice.
Latest Events
- DEC312024
According to OpenSecrets data, Vaxcyte Inc spent $30,000 on federal lobbying activities during 2024. The expenditure reflects the company's engagement in political advocacy, which raises concerns about corporate influence on public policy.
-40
Political Contributions and Lobbying Efforts
April 1
The $30,000 lobbying expenditure, although modest in monetary terms, signals an effort by Vaxcyte to influence legislative outcomes. From an anti-fascist perspective, corporate political spending is concerning as it can contribute to undemocratic processes and excessive corporate influence in policymaking.
- DEC312024
Vaxcyte Inc spent $30,000 on lobbying efforts during 2024, as outlined by OpenSecrets, suggesting a strategy to influence public policy which may undermine broader democratic accountability.
-20
Political Contributions and Lobbying Efforts
April 1
The reported $30,000 expense on lobbying indicates that Vaxcyte Inc is actively engaging in political influence activities. From a progressive, anti-fascist perspective, this use of corporate funds to sway public policy is concerning, as it may serve to favor private interests over societal welfare and democratic integrity.
Alternatives
Indianapolis, United States
-35.34
Menlo Park, United States
-49.80
Corporation
0.00
Belgium (Ghent), Belgium
79.03
Raleigh, USA
56.52
New York, United States
30.41
Bagsværd, Denmark
16.06
Darmstadt, Germany
12.29
Kenilworth, United States
2.89
Copenhagen, Denmark
2.36
Corporate Financials
- Revenue
- 2025
- $32.00M
- Total Assets
- 2025
- $110.00M
- Operating Income
- 2025
- -$29.00M
- Total Equity
- 2025
- $75.00M
Employees: 150
Industries
- 325412
- Pharmaceutical Preparation Manufacturing
- 541715
- Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- 541711
- Research and Development in Biotechnology